Lista de obras -

A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response

scientific article published on 03 May 2020

A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.

artículo científico publicado en 2006

Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.

artículo científico

Acute decline in renal function, inflammation, and cardiovascular risk after an acute coronary syndrome

scientific article published on 09 October 2009

An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design

artículo científico publicado en 2010

Atherosclerotic disease in non-insulin-dependent diabetes mellitus: role of abnormal lipids and the place for lipid-altering therapies

artículo científico publicado en 1999

Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention

artículo científico publicado en 2017

Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).

artículo científico publicado en 2017

Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function

artículo científico publicado en 2017

Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial

artículo científico publicado en 2019

Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial

artículo científico publicado en 2006

Competing Risks of Cardiovascular Versus Noncardiovascular Death During Long-Term Follow-Up After Acute Coronary Syndromes

artículo científico publicado en 2017

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

artículo científico publicado en 2004

Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial

scientific article published on 17 July 2019

Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trial

artículo científico publicado en 2007

Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials

artículo científico publicado en 2008

Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS).

artículo científico publicado en 2003

Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials

artículo científico publicado en 2006

Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).

artículo científico publicado en 2017

Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview

artículo científico publicado en 2004

Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia

artículo científico publicado en 2004

Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial

artículo científico publicado en 2004

Estimated glomerular filtration rate, inflammation, and cardiovascular events after an acute coronary syndrome

artículo científico publicado en 2008

Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population

artículo científico publicado en 2014

Evaluation of the National Cholesterol Education Program Adult Treatment Panel III algorithm for selecting candidates for statin therapy: insights from the A to Z trial

artículo científico publicado en 2006

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

artículo científico publicado en 2015

Ezetimibe plus a Statin after Acute Coronary Syndromes

artículo científico publicado en 2015

Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International T

artículo científico

Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older-Reply

artículo científico publicado en 2020

Is rhythm-control superior to rate-control in patients with atrial fibrillation and diastolic heart failure?

artículo científico publicado en 2010

Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations

artículo científico publicado en 2020

Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial

artículo científico

Medication Discontinuation in the IMPROVE-IT Trial

scientific article published on 01 January 2019

Muscle Complaints or Events in Patients Randomized to Simvastatin or Ezetimibe/Simvastatin

artículo científico publicado en 2020

Natural History of Patients Postacute Coronary Syndrome Based on Heart Failure Status

artículo científico publicado en 2018

On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT).

artículo científico publicado en 2016

Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).

artículo científico publicado en 2008

Patient Phenotypes, Cardiovascular Risk, and Ezetimibe Treatment in Patients After Acute Coronary Syndromes (from IMPROVE-IT)

artículo científico publicado en 2019

Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial

artículo científico publicado en 2018

Premature release of data from clinical trials of ezetimibe

artículo científico publicado en 2009

Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).

artículo científico publicado en 2017

Prognostic value of anxiety and depression in patients with chronic heart failure

artículo científico publicado en 2004

Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease

artículo científico

Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes

artículo científico publicado en 2008

Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial

artículo científico publicado en 2016

Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure

artículo científico publicado en 2001

Reply: Adding Ezetimibe to Simvastatin for the Secondary Prevention of Cardiovascular Disease: Is it Useful?

artículo científico publicado en 2016

Reply: Personalize and Optimize Lipid-Lowering Therapies

artículo científico publicado en 2016

Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE

artículo científico publicado en 2016

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis

artículo científico publicado en 2011

Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial

artículo científico publicado en 2004

Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial

artículo científico publicado en 2007

Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF

artículo científico publicado en 2018

The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy

artículo científico publicado en 2001

The association between depression and chronic kidney disease and mortality among patients hospitalized with congestive heart failure

artículo científico publicado en 2004

The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial

artículo científico publicado en 2016

The benefit of implementing a heart failure disease management program

artículo científico publicado en 2001

The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe

artículo científico publicado en 2018

Lista de obras de

A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response

A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.

Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.

Acute decline in renal function, inflammation, and cardiovascular risk after an acute coronary syndrome

An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design

Atherosclerotic disease in non-insulin-dependent diabetes mellitus: role of abnormal lipids and the place for lipid-altering therapies

Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention

Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).

Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function

Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial

Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial

Competing Risks of Cardiovascular Versus Noncardiovascular Death During Long-Term Follow-Up After Acute Coronary Syndromes

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial

Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trial

Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials

Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS).

Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials

Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).

Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview

Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia

Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial

Estimated glomerular filtration rate, inflammation, and cardiovascular events after an acute coronary syndrome

Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population

Evaluation of the National Cholesterol Education Program Adult Treatment Panel III algorithm for selecting candidates for statin therapy: insights from the A to Z trial

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

Ezetimibe plus a Statin after Acute Coronary Syndromes

Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International T

Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older-Reply

Is rhythm-control superior to rate-control in patients with atrial fibrillation and diastolic heart failure?

Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations

Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial

Medication Discontinuation in the IMPROVE-IT Trial

Muscle Complaints or Events in Patients Randomized to Simvastatin or Ezetimibe/Simvastatin

Natural History of Patients Postacute Coronary Syndrome Based on Heart Failure Status

On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT).

Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).

Patient Phenotypes, Cardiovascular Risk, and Ezetimibe Treatment in Patients After Acute Coronary Syndromes (from IMPROVE-IT)

Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial

Premature release of data from clinical trials of ezetimibe

Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).

Prognostic value of anxiety and depression in patients with chronic heart failure

Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease

Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes

Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial

Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure

Reply: Adding Ezetimibe to Simvastatin for the Secondary Prevention of Cardiovascular Disease: Is it Useful?

Reply: Personalize and Optimize Lipid-Lowering Therapies

Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis

Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial

Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial

Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF

The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy

The association between depression and chronic kidney disease and mortality among patients hospitalized with congestive heart failure

The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial

The benefit of implementing a heart failure disease management program

The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe